 | • レポートコード：MRC2303L187 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、221ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医薬品 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査レポートでは、2021年に1,075.85百万ドルであった世界の点眼薬市場規模が2022年に1,149.39百万ドルとなり、2027年までに年平均7.01％拡大して1,615.79百万ドルに達すると予測されています。本書では、点眼薬の世界市場を対象に総合的に調査・分析を行い、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、種類別（OTC点眼薬、処方点眼薬）分析、カテゴリー別（麻酔薬、抗生物質、拡張剤、緑内障治療薬、ステロイド）分析、エンドユーザー別（眼科クリニック、病院、医療機関、研究機関）分析、疾患別（加齢性黄斑変性症、白内障、緑内障、炎症性疾患、屈折障害）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などの構成でまとめております。なお、本書に掲載されている企業情報には、AbbVie Inc.、Akorn, Inc.、Alcon Inc.、Apotex Inc.、Arizona、Bausch & Lomb Incorporated、Duopharma Biotech Berhad、Geri-Care Pharmaceuticals Corp.、Honeywell International Inc.、ImprimisRx、Johnson & Johnson Services, Inc.、KC Pharmaceuticalsなどが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の点眼薬市場規模：種類別 - OTC点眼薬の市場規模 - 処方点眼薬の市場規模 ・世界の点眼薬市場規模：カテゴリー別 - 麻酔薬の市場規模 - 抗生物質の市場規模 - 拡張剤の市場規模 - 緑内障治療薬の市場規模 - ステロイドの市場規模 ・世界の点眼薬市場規模：エンドユーザー別 - 眼科クリニックにおける市場規模 - 病院における市場規模 - 医療機関における市場規模 - 研究機関における市場規模 ・世界の点眼薬市場規模：疾患別 - 加齢性黄斑変性症における市場規模 - 白内障における市場規模 - 緑内障における市場規模 - 炎症性疾患における市場規模 - 屈折障害における市場規模 ・世界の点眼薬市場規模：地域別 - 南北アメリカの点眼薬市場規模 アメリカの点眼薬市場規模 カナダの点眼薬市場規模 ブラジルの点眼薬市場規模 ... - アジア太平洋の点眼薬市場規模 日本の点眼薬市場規模 中国の点眼薬市場規模 インドの点眼薬市場規模 韓国の点眼薬市場規模 台湾の点眼薬市場規模 ... - ヨーロッパ/中東/アフリカの点眼薬市場規模 イギリスの点眼薬市場規模 ドイツの点眼薬市場規模 フランスの点眼薬市場規模 ロシアの点眼薬市場規模 ... - その他地域の点眼薬市場規模 ・競争状況 ・企業情報 |
The Global Ophthalmic Drops Market size was estimated at USD 1,075.85 million in 2021 and expected to reach USD 1,149.39 million in 2022, and is projected to grow at a CAGR 7.01% to reach USD 1,615.79 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Ophthalmic Drops to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Type, the market was studied across Over-the-counter Eye Drops and Prescription Eye Drops.
Based on Category, the market was studied across Anesthetic Drops, Antibiotic Drops, Dilation Drops, Glaucoma Drops, and Steroid Drops.
Based on End User, the market was studied across Eye Clinic, Hospitals, Medical Institutes, and Research Organizations.
Based on Indications, the market was studied across Age-Related Macular Degeneration, Cataract, Glaucoma, Inflammatory Diseases, and Refractive Disorders.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across Arizona, California, Florida, Illinois, Massachusetts, Nevada, New Jersey, North Carolina, Ohio, Pennsylvania, Texas, and Washington. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Ophthalmic Drops market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Ophthalmic Drops Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Ophthalmic Drops Market, including AbbVie Inc., Akorn, Inc., Alcon Inc., Apotex Inc., Arizona, Bausch & Lomb Incorporated, Duopharma Biotech Berhad, Geri-Care Pharmaceuticals Corp., Honeywell International Inc., ImprimisRx, Johnson & Johnson Services, Inc., KC Pharmaceuticals, Inc., Massachusetts, Nevada, New Jersey, North Carolina, Novartis AG, OCuSOFT, Inc., Orimed Pharma Inc., Pfizer, Inc., Preferred Pharmaceuticals Inc., Prestige Consumer Healthcare Inc., ROHTO Pharmaceutical Co., Ltd., Sager Pharma Kft., Santen Pharmaceutical Co., Ltd., Similasan Corporation, Teva Pharmaceutical Industries Ltd., and Washington.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Ophthalmic Drops Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Ophthalmic Drops Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Ophthalmic Drops Market?
4. What is the competitive strategic window for opportunities in the Global Ophthalmic Drops Market?
5. What are the technology trends and regulatory frameworks in the Global Ophthalmic Drops Market?
6. What is the market share of the leading vendors in the Global Ophthalmic Drops Market?
7. What modes and strategic moves are considered suitable for entering the Global Ophthalmic Drops Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising Prevalence of Ophthalmic Disease and Eye Infection among the Population
5.1.1.2. Growing Old Age Population and Associated Eye-Surgeries Worldwide
5.1.1.3. Growth of Vision Problems in Kids and Younger Population due to More Screen Time
5.1.2. Restraints
5.1.2.1. Systemic Side Effects of Ophthalmic Drops
5.1.3. Opportunities
5.1.3.1. New Research & Development Approach to Ophthalmic Drops
5.1.3.2. Increase in Investment for Ophthalmology Medication
5.1.4. Challenges
5.1.4.1. Patient-Reported Problems Related to Eye Drop Instillation and Product Recall
5.2. Cumulative Impact of COVID-19
6. Ophthalmic Drops Market, by Type
6.1. Introduction
6.2. Over-the-counter Eye Drops
6.3. Prescription Eye Drops
7. Ophthalmic Drops Market, by Category
7.1. Introduction
7.2. Anesthetic Drops
7.3. Antibiotic Drops
7.4. Dilation Drops
7.5. Glaucoma Drops
7.6. Steroid Drops
8. Ophthalmic Drops Market, by End User
8.1. Introduction
8.2. Eye Clinic
8.3. Hospitals
8.4. Medical Institutes
8.5. Research Organizations
9. Ophthalmic Drops Market, by Indications
9.1. Introduction
9.2. Age-Related Macular Degeneration
9.3. Cataract
9.4. Glaucoma
9.5. Inflammatory Diseases
9.6. Refractive Disorders
10. Americas Ophthalmic Drops Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Ophthalmic Drops Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Ophthalmic Drops Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. AbbVie Inc.
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. Akorn, Inc.
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. Alcon Inc.
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. Apotex Inc.
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. Arizona
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. Bausch & Lomb Incorporated
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. Duopharma Biotech Berhad
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. Geri-Care Pharmaceuticals Corp.
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. Honeywell International Inc.
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. ImprimisRx
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
14.11. Johnson & Johnson Services, Inc.
14.11.1. Business Overview
14.11.2. Key Executives
14.11.3. Product & Services
14.12. KC Pharmaceuticals, Inc.
14.12.1. Business Overview
14.12.2. Key Executives
14.12.3. Product & Services
14.13. Massachusetts
14.13.1. Business Overview
14.13.2. Key Executives
14.13.3. Product & Services
14.14. Nevada
14.14.1. Business Overview
14.14.2. Key Executives
14.14.3. Product & Services
14.15. New Jersey
14.15.1. Business Overview
14.15.2. Key Executives
14.15.3. Product & Services
14.16. North Carolina
14.16.1. Business Overview
14.16.2. Key Executives
14.16.3. Product & Services
14.17. Novartis AG
14.17.1. Business Overview
14.17.2. Key Executives
14.17.3. Product & Services
14.18. OCuSOFT, Inc.
14.18.1. Business Overview
14.18.2. Key Executives
14.18.3. Product & Services
14.19. Orimed Pharma Inc.
14.19.1. Business Overview
14.19.2. Key Executives
14.19.3. Product & Services
14.20. Pfizer, Inc.
14.20.1. Business Overview
14.20.2. Key Executives
14.20.3. Product & Services
14.21. Preferred Pharmaceuticals Inc.
14.21.1. Business Overview
14.21.2. Key Executives
14.21.3. Product & Services
14.22. Prestige Consumer Healthcare Inc.
14.22.1. Business Overview
14.22.2. Key Executives
14.22.3. Product & Services
14.23. ROHTO Pharmaceutical Co., Ltd.
14.23.1. Business Overview
14.23.2. Key Executives
14.23.3. Product & Services
14.24. Sager Pharma Kft.
14.24.1. Business Overview
14.24.2. Key Executives
14.24.3. Product & Services
14.25. Santen Pharmaceutical Co., Ltd.
14.25.1. Business Overview
14.25.2. Key Executives
14.25.3. Product & Services
14.26. Similasan Corporation
14.26.1. Business Overview
14.26.2. Key Executives
14.26.3. Product & Services
14.27. Teva Pharmaceutical Industries Ltd.
14.27.1. Business Overview
14.27.2. Key Executives
14.27.3. Product & Services
14.28. Washington
14.28.1. Business Overview
14.28.2. Key Executives
14.28.3. Product & Services
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing